Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial

Trial Profile

Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2018

At a glance

  • Drugs Denosumab (Primary) ; Nivolumab (Primary) ; Calcium; Vitamin D
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Acronyms POPCORN
  • Most Recent Events

    • 10 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top